NCT06874751View on ClinicalTrials.gov

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

CompletedOBSERVATIONAL

Enrollment

45,456

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

March 28, 2025

Conditions

OverweightObesityAtherosclerotic Cardiovascular Disease (ASCVD)

Interventions

OTHER

No treatment given

No treatment given

OTHER

No treatment given

No treatment given

Trial Locations (1)

08536

Novo Nordisk Investigational Site, Plainsboro

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY